Last reviewed · How we verify

NCT05112978

Evaluation of Patellar Dimension and Bristol Index in Asian Population

Completed Last updated 9 November 2021
What this trial tests

trial testing MRI in Patello Femoral Syndrome in 101 participants. Completed in 31 January 2021.

Timeline
1 January 2019
Primary endpoint
31 December 2020
31 January 2021

Quick facts

Lead sponsorIndonesia University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment101
Start date1 January 2019
Primary completion31 December 2020
Estimated completion31 January 2021
Sites1 location across Indonesia

Drugs / interventions tested

Conditions studied

Sponsor

Indonesia University

Who can join

Adults 17 to 40, any sex, with Patello Femoral Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Restoration of patellar thickness is pivotal during a total knee arthroplasty (TKA). Several studies showed there are differences in the knee measurements between Asian and Western population. This study aims to evaluate the patellar dimension and Bristol Index of patellar width to thickness (BIPWiT) using magnetic resonance imaging (MRI) in Asian population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluation of patellar dimension and Bristol Index in Asian population: An MRI study.
    Pontoh LA, Dilogo IH, Rahyussalim AJ, Widodo W, et al · · 2021 · cited 2× · PMID 34849220 · DOI 10.1016/j.amsu.2021.103072

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other recruiting trials for Patello Femoral Syndrome

Currently open trials in the same condition.

Other Indonesia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05112978.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing